Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Trinity Biotech plc

Trinity Biotech ( ($TRIB) ) has provided an announcement. On June 16, 2026, Trinity Biotech reported that it had secured new purchase orders for mo...

Trinity Biotech Wins Major TrinScreen HIV Orders and Posts Strong Q1 2026 Turnaround

Trinity Biotech ( ($TRIB) ) has issued an update. On June 12, 2026, Trinity Biotech plc entered into a new at-the-market equity offering agreement ...

Trinity Biotech Launches New $4.35 Million ATM Program with Lucid, Ends Craig-Hallum Mandate

The latest announcement is out from Trinity Biotech ( ($TRIB) ). Trinity Biotech plc disclosed that it has reached an agreement with its lender, Pe...

Market Cap	$11.54M	P/E Ratio	NaN
52W High	$17.20	52W Low	$0.50
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-100.0%	52W Position	0.5%
Overall Score	31	Value Score	40
Quality Score	26	Technical Score	27

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TRIB	$0.58	+0.34%	135.15K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TRIB	$0.58	+0.3%	135.15K
3
4
5
6

TRIB

TRIB

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Trinity Biotech plc Data in Excel

Get Trinity Biotech plc Data in Excel